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Abstract 
This study evaluated the prevention of bone fragility fractures in a 
representative sample of four Irish general practices. The clinical records of 
243 patients potentially at risk of bone fragility were studied. One hundred and 
fourteen (47%) had a dual energy x-ray absorptiometry (DEXA) scan. 
Osteoporosis was established in 42 (17%) and osteopaenia in 28 (11%). One 
hundred and fifty-two (63%) were currently being prescribed bisphosphonates. 
Thirty-four (22%) of those on bisphosphonates did not have a baseline DEXA 
scan performed prior to commencing treatment and further analysis did not 
show a clear rationale for initiation of the treatment in this group of patients. 
Forty-six (30%) patients on bisphosphonates had been prescribed them for 
over 5 years without any apparent review to see if they were still indicated. 
There was no record of any of the practices having carried out a fracture risk 
score assessment prior to commencing bone fragility treatment. The 
implications are that bone fragility management warrants urgent review. 
 
Introduction 
Osteoporosis is characterised by low bone mass and structural deterioration of bone 
tissue, with a consequent increase in bone fragility and susceptibility to fracture, 
particularly fractures that result from mechanical forces that would not ordinarily 
result in fracture, known as fragility fractures1. Osteopaenia is a less severe form of 
osteoporosis but is also associated with an increased risk of fracture2. The burden of 
osteoporosis in Ireland is substantial and increasing3, 4. The prevalence of 
osteoporosis rises markedly with age and it is estimated that approximately 50% of 
women and 20% of men aged over 50 years’ experience an osteoporosis-related 
facture at some point in their lifetime5. With an increasingly elderly population this 
has become an extremely important health issue6. 
Risk of fracture is also increased by factors such as lifestyle, drug treatments, family 
history, and other conditions that cause secondary osteoporosis7, 8. Large 
randomised controlled trials have shown that bisphosphonate therapy for 3 to 4 
years is effective in reducing the risk of both non-vertebral and vertebral fractures in 
osteoporotic women8. 
However, there is considerable controversy over the optimal duration of anti-
resorptive therapy, particularly since the reporting of side-effects, including atypical 
subtrochanteric fractures during long-term bisphosphonate therapy9, 10. 
The Fracture Risk Assessment Tool “FRAX” was developed in 2008 to provide a 
prediction tool for assessing an individual’s risk of fracture in order to provide general 
clinical guidance for treatment decisions11. It has been adapted to the Irish population 
using estimates about life expectancy and fracture incidence in Ireland. It is readily 
calculated at the time of DEXA scan. 
Prior to prescribing anti-resorbtive medication for patients, the National Institute for 
Health and Clinical Excellence (NICE) published recommendations on the process of 
risk assessment of fragility fractures which should be undertaken1. These have been 
updated more recently, but their fundamental recommendations regarding initial 
assessment and prescription of anti-resorbtive medications remain unchanged12. The 
overarching aim of this study was to determine if the prevention and management of 
bone fragility fractures in an Irish general practice setting adhere to best practice 
guidelines. Specific objectives were to review bone strengthening prescriptions 
including those for bisphosphonates and calcium/vitamin D combinations and to 
investigate how the risk of bone fragility fractures is being assessed. 
 
Methods 
Four practices affiliated with the University of Limerick Graduate Entry Medical 
School with a senior medical student on general practice placement in 2012/13 
participated in this study. The practices were based in two of Ireland’s four 
healthcare regions (South, West) and are broadly representative of general practices 
nationally by size, patient eligibility for free medical care and urban/rural location7. 
Third year medical students on placement and their general practitioner supervisors 
used reporting functions of electronic practice management systems to generate a 
list of all patients who were either on bisphosphonate therapy currently, or were 
females aged over 65 years and therefore at risk of having osteoporosis or bone 
fragility. A random sample was then generated using a random number function in 
Microsoft Excel. 
Three practices were fully computerised, one was not. All practices had a full time 
secretary and practice nurse. Practice 1 was a rural singlehanded and collected data 
on 86 female patients aged over 65 years. Practice 2 was a rural group and collected 
data on 50 female patients aged over 65 years. Practice 3 was an urban group and 
collected data on 47 patients who were already on bisphosphonate therapy. Practice 
4 was also an urban group and collected data on 60 patients who were already on 
bisphosphonate therapy. 
Records were then checked for the presence of a fragility fracture risk assessment 
prior to or during bisphosphonate prescription. The clinical records of a subsample 
that were prescribed bisphosphonates were studied for documented indications for 
initial prescription and duration of treatment. The proportion of patients who had a 
Dual Energy X-ray Absorptiometry (DEXA) scan was also studied. DEXA scan 
results, if present, were analysed in all patients. Osteopaenia was diagnosed when 
bone mineral density (BMD), as measured by DEXA scanning, was less than one 
standard deviation (SD) of young adult female reference mean but greater than 
minus 2.5 SD. Osteoporosis was diagnosed when the DEXA result was less than 
minus 2.5 SD. 
 
Results 
A total of 243 patient records were studied: 136 from the rural practices and 107 
from the urban practices. The overall features of the practices studied are 
summarised in table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Bisphosphonate group 
Sixty-three percent of total study population (152 patients) were currently being 
prescribed bisphosphonates. This figure was made up of all of the 107 patients 
currently on bisphosphonates plus 45 from the group of females aged over 65 years. 
See tables 2 and 3. 
Thirty-three percent of the 136 females aged over 65 years (45 patients) were being 
prescribed bisphosphonates. This number was greater than all the patients with 
DEXA diagnosed osteoporosis (13%; N = 18) and osteopaenia (15%; N= 21) 
combined in this category. 
22% of the 136 females aged over 65 years (30 patients) were being prescribed 
calcium and vitamin D supplements. This parameter was not studied in the study 
group who were prescribed bisphosphonates. In one practice where 47 patients 
were on bisphosphonates and where the DEXA results were analysed, osteoporosis 
was established in 51% (24 patients), and osteopaenia in a further 15% (7 patients). 
Thus, 34% of patients on bisphosphonates had a normal DEXA scan. Further 
analysis of these patients’ files showed that these patients had other risk factors for 
bone fragility: being prescribed on high dose steroids, had rheumatoid disease or x 
ray changes suggesting reduced bone density. However in another practice studied, 
57% (34 patients) of those on bisphosphonates had not had any baseline DEXA 
scan performed prior to commencing treatment and further analysis did not show a 
clear rationale for initiation of the treatment. Of those being prescribed 
bisphosphonates, 30% (46 patients) had been prescribed the drugs for over 5 years 
without any apparent review to see if they were still required. There was no record of 
any of the practices having carried out a fracture risk score assessment prior to 
commencing bisphosphonate therapy. 
Discussion 
Our study has shown that fracture risk assessment using tools such as FRAX or 
QFracture did not seem to take place in many patients prior to commencement of 
bone strengthening treatments in the form of bisphosphonates and or calcium / 
vitamin D supplementation. 
It is possible that such risk assessment may have been done in the practices and no 
specific record made of the exercise. Many patients prescribed bisphosphonates did 
not have bone density assessed beforehand. Also 30% of those being prescribed 
bisphosphonates were taking them for over 5 years without any indication that a 
review had taken place to consider stopping them or switching to another treatment8. 
Whatever the reason they were initiated, our study showed that of the 92 patients 
being prescribed bisphosphonates where the indication was studied, only 46% (42 
patients) had DEXA confirmed osteoporosis. Many of these patients may well have 
been taking the bisphosphonates with little benefit and potential risk of harm10, 13. 
Neither was there any indication of the use of non-drug measures, which are also 
recommended for the building up of bone mass and prevention of fractures14. GPs 
should also ensure that their patients have an adequate intake of calcium and 
vitamin D, avoiding excessive intake, in line with international guidelines15. It has also 
been suggested that calcium intake should be estimated at the time of DEXA 
scanning to guide supplementation needs16. 
Traditionally the measure of bone mineral density was used to assess patients’ risk 
of future fractures17. The development of fracture risk assessment tools (FRAX11 and 
Q Fracture18)  has led to a fundamental shift in the approach to risk assessment. 
They have become a crucial part of the assessment of patients fracture risk before a 
decision is made to commence any form of bone strengthening treatment1, 12, 19. A 
recent population study demonstrated that the prevalence of people at risk of bone 
fragility is much higher than documented osteoporosis or than the number of people 
taking bone strengthening medications20. 
Our findings are consistent with Ewald’ review of bone fragility prevention and early 
intervention which showed less than adequate delivery of these in Australian general 
practice21. Even the NICE guideline on the topic of osteoporosis and assessing the 
risk of fragility fracture declares that identifying who will benefit from preventative 
treatment is imprecise1. There appears to be a significant amount of confusion 
currently in the screening for and treatment of bone fragility in Irish general practice 
with a view to preventing fractures. 
To our knowledge this is the first study carried out of the assessment and 
management of bone fragility in Irish general practice. It provides an accurate picture 
of current practice in the detection and management of bone fragility to prevent 
fractures. 
It is important to consider context when analysing studies such this in general 
practice. GPs are busy clinicians who deal with a variety of problems, one of the 
most challenging being multi-morbidity22. It is unrealistic to expect GPs to think of and 
complete all parameters in all conditions in an un-resourced and unstructured work 
environment. Success has been previously documented in diabetes care when a 
standardised and resourced approach was introduced23. This could be used as a 
paradigm for the management of other chronic illnesses such as bone fragility in a 
community setting. 
The strengths of this study are that the data was directly taken from the practice 
patient records by experienced students and is therefore accurate and not subject to 
recall bias. 
The weaknesses are that not all the data was analysed in a standardised manner. 
Hence not all the data could be included in this analysis. Future research should 
involve a larger sample size of GPs, investigating the use of validated fracture risk 
assessment tools and the factors involved in the decision to commence bone 
strengthening medication. 
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